Orrin Hatch: “Has FDA analyzed, No. 1, the extent to which these cost of changing…”

On the recordSeptember 16, 2015

Has FDA analyzed, No. 1, the extent to which these cost of changing names is passed on to healthcare payers and consumers?

Said by

Republican · Utah

Source

Senator Hatch questions FDA about cost impacts on healthcare from name changes.

More from Orrin Hatch

Oct 1, 2018

Having a confirmed Commissioner, and sustained leadership, will benefit the Social Security Administration.

Oct 1, 2018

Having a confirmed Commissioner and sustained leadership will benefit the Social Security Administration.

Oct 1, 2018

I stand by everything I said during my questioning of Mr. Saul, including concerns about budget summary data.

Dec 10, 2018

It has been one of the great honors of my life to serve on this committee.

Other voices in this conversation

Orrin Hatch: “Has FDA analyzed, No. 1, the extent to which these cost of changing names is passed on to healthcare payers and…”